A
74
5
FAST
59
4
NEM
55
6
MNST
55
3
DTE
54
4
DRI
56
3
CHK
49
4
SRCL
48
2
AON
67
2
CAG
58
3
ROK
70
3
MSI
55
5
ALLE
64
2
DIS
60
4
CTAS
52
3
WMT
46
-12
ADBE
56
2
HPE
72
13
AAP
40
12
SRE
73
4
A
74
5
FAST
59
4
NEM
55
6
MNST
55
3
DTE
54
4
DRI
56
3
CHK
49
4
SRCL
48
2
AON
67
2
CAG
58
3
ROK
70
3
MSI
55
5
ALLE
64
2
DIS
60
4
CTAS
52
3
WMT
46
-12
ADBE
56
2
HPE
72
13
AAP
40
12
SRE
73
4
Financhill
Back

NovoCure Quote, Financials, Valuation and Earnings

Sell
50

NVCR
NovoCure

Last Price:
76.84
Seasonality Move:
0.73%

7 Day Trial

ALL ACCESS PASS

$ 7

NovoCure Price Quote

$76.84

NovoCure Key Stats

Sell
50
NovoCure (NVCR) is a Sell
Day range:
$72.89 - $76.91
52-week range:
$56.39 - $101.62
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
14.67
P/B ratio:
18.26%
Volume:
841.9K
Avg. volume:
513.1K
1-year change:
-17.94%
Market cap:
$8.1B
Revenue:
$535M
EPS:
$-0.65

How Much Does NovoCure Make?

  • How Much Are NovoCure's Sales Annually?
    NVCR Revenues are $535M
  • How Much Profit Does NovoCure's Make A Year?
    NVCR net income is -$58.4M

Is NovoCure Growing As A Company?

  • What Is NovoCure's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.06%
  • What Is NovoCure's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

NovoCure Stock Price Performance

  • Did NovoCure Stock Go Up Last Month?
    NovoCure share price went up by 9.68% last month
  • Did NVCR's Share Price Rise Over The Last Year?
    NVCR share price fell by -17.94% over the past 1 year

What Is NovoCure 52-Week High & Low?

  • What Is NovoCure’s 52-Week High Share Price?
    NovoCure has traded as high as $101.62 over the past 52 weeks
  • What Is NovoCure’s 52-Week Low Share Price?
    NovoCure has traded as low as $56.39 over the past 52 weeks

NovoCure Price To Free Cash Flow

  • Is NovoCure Stock Overvalued?
    NovoCure is trading at a price to free cash flow ratio of 332.16
  • Is NovoCure Stock Undervalued?
    NovoCure EV to Free Cash Flow ratio is 309.46
  • What Is NovoCure’s Price Earnings Growth Ratio?
    NVCR PEG ratio is -0.10
  • Is NovoCure Trading At A Premium To Earnings?
    NovoCure EV to EBIT ratio is 0.00

Is It Risky To Buy NovoCure?

  • How Much Debt Does NovoCure Have?
    Total long term debt quarterly is $563.8M
  • How Much Cash Does NovoCure Have?
    Cash and short term investments quarterly total is $948.5M
  • What Is NovoCure’s Book Value Per Share?
    Book value per share is 4.22

Is NovoCure Cash Flow Positive?

  • What Is NVCR Cash Flow From Operations?
    Cash flow from operations (TTM) is $50.9M
  • What Is NovoCure’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $14.6M
  • What Is NovoCure’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$58M

NovoCure Return On Invested Capital

  • Is Management Doing A Good Job?
    NVCR return on invested capital is -6.95%
  • What Is NovoCure Return On Assets?
    ROA measures how assets are converting to revenues and is -6.02%
  • What Is NVCR Return On Equity?
    ROE is a measure of profitability and is -16.26%

NovoCure Earnings Date & Stock Price

  • What Is NovoCure's Stock Price Today?
    A single share of NVCR can be purchased today for 76.84
  • What Is NovoCure’s Stock Symbol?
    NovoCure trades on the nasdaq under the ticker symbol: NVCR
  • When Is NovoCure’s Next Earnings Date?
    The next quarterly earnings date for NovoCure is scheduled on February 24, 2023
  • When Is NVCR's next ex-dividend date?
    NovoCure's next ex-dividend date is December 1, 2022
  • How To Buy NovoCure Stock?
    You can buy NovoCure shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

NovoCure Competitors

  • Who Are NovoCure's Competitors?
    Below is a list of companies who compete with NovoCure or are related in some way:
    • Agios Pharmaceuticals Inc (AGIO)
    • Moderna Inc (MRNA)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Sage Therapeutics Inc (SAGE)
    • Sarepta Therapeutics Inc (SRPT)

NovoCure Dividend Yield

Data Unavailable

NovoCure Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 2.77%
Revenue: 5.5% -1.79%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 2
Sell Recommendations: 2
Price Target: 91.25
Upside from Last Price: 18.75%

Major Shareholders

  • How many NVCR shares are owned by institutional investors?
    173.3M NVCR shares are owned by institutional investors
  • How many NVCR shares are owned by insiders?
    8.1M NVCR shares are owned by insiders